NRx, a niche drug company founded in 2009 by Dr. Deanna J. Nelson and headquartered in Cary, NC, reformulates important drugs to eliminate their side effects. Reformulation provides a patented drug that can be approved quickly by the FDA and enter a large existing market as a branded drug. Market entry by generic copies of the reformulated drug will be delayed by law for a period of 3 years or more. NRx will use the FDA’s 505(b)(2) New Drug Application process to commercialize NRx’s lead reformulated drug candidate MagneVal™, a patent-protected new treatment for epilepsy. NRx has 3 employees who will direct rapid FDA approval and drug commercialization at a cost at least 60% to 70% less than innovator products. The team will also ensure achievement of the long-term objectives of outstanding profitability and return on investment.
